Treatment of Acute Venous Thromboembolism

被引：3
|
作者：
Nair, Sashi [1 ]
Garza, Nina [1 ]
George, Matt [2 ]
Kaatz, Scott [3 ]
机构：
[1] Henry Ford Hosp, Dept Med, 2799 West Grand Blvd, Detroit, MI 48202 USA
[2] Henry Ford West Bloomfield Hosp, Div Hosp Med, 6777 West Maple Rd, W Bloomfield, MI 48322 USA
[3] Henry Ford Hosp, Div Hosp Med, 2799 West Grand Blvd, Detroit, MI 48202 USA
来源：
MEDICAL CLINICS OF NORTH AMERICA | 2020年 / 104卷 / 04期
关键词：
Deep vein thrombosis; Pulmonary embolism; Anticoagulation; Thrombolytic; Risk stratification; ACUTE PULMONARY-EMBOLISM; DIRECT ORAL ANTICOAGULANTS; CATHETER-DIRECTED THROMBOLYSIS; INTENSITY WARFARIN THERAPY; VITAMIN-K ANTAGONISTS; DEEP-VEIN THROMBOSIS; ANTITHROMBOTIC THERAPY; EXTENDED TREATMENT; MULTICENTER TRIAL; INITIAL TREATMENT;
D O I：
10.1016/j.mcna.2020.03.004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Acute venous thromboembolism is a common disease seen by nearly all hospitalists. The advent of low molecular weight heparin (LMWH) several decades ago ushered in the era of early hospital discharge and home treatment. More recently, the direct oral anticoagulants (DOACs) have further simplified outpatient treatment and some offer treatment without parenteral therapy. Use of DOACs for cancer-associated venous thromboembolism is emerging and is a welcome evolution of care to spare oncologic patients the burden of daily LMWH injections.
引用
收藏
页码：631 / +
页数：17
相关论文
共 50 条
12345